Patents by Inventor Jinglan Zhou

Jinglan Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230233560
    Abstract: The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
    Type: Application
    Filed: July 14, 2022
    Publication date: July 27, 2023
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Mark Thomas Miller, Corey Anderson, Vijayalaksmi Arumugam, Brian Richard Bear, Hayley Marie Binch, Jeremy J. Clemens, Thomas Cleveland, Erica Conroy, Timothy Richard Coon, Bryan A. Frieman, Peter Diederik Jan Grootenhuis, Raymond Stanley Gross, Sara Sabina Hadida-Ruah, Haripada Khatuya, Pramod Virupax Joshi, Paul John Krenitsky, Chun-Chieh Lin, Gulin Erdogan Marelius, Vito Melillo, Jason McCartney, Georgia McGaughey Nicholls, Fabrice Jean Denis Pierre, Alina Silina, Andreas P. Termin, Johnny Uy, Jinglan Zhou
  • Patent number: 11639347
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: May 2, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sara S. Hadida Ruah, Peter D. J. Grootenhuis, Fredrick Van Goor, Jinglan Zhou, Brian Bear, Mark T. Miller, Jason McCartney, Mehdi Michel Jamel Numa, Xiaoqing Yang
  • Publication number: 20230127655
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: March 11, 2022
    Publication date: April 27, 2023
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Sara Sabina HADIDA RUAH, Peter Diederik Jan GROOTENHUIS, Fredrick F. VAN GOOR, Jinglan ZHOU, Brian Richard BEAR, Mark Thomas MILLER, Jason McCARTNEY, Mehdi Michel Djamel NUMA
  • Publication number: 20230100634
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: March 30, 2021
    Publication date: March 30, 2023
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Sara Sabina HADIDA RUAH, Peter Diederik Jan GROOTENHUIS, Fredrick F. VAN GOOR, Jinglan ZHOU, Brian Richard BEAR, Mark Thomas MILLER, Jason McCARTNEY, Mehdi Michel Djamel NUMA
  • Publication number: 20230099745
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.
    Type: Application
    Filed: November 17, 2021
    Publication date: March 30, 2023
    Inventors: Jeremy J. Clemens, William Schulz Bechara, Brett C. Bookser, Thomas Cleveland, Timothy R. Coon, Michel Gallant, Peter Grootenhuis, Sara Sabina Hadida Ruah, Julie Laterreur, Mark Thomas Miller, Prasuna Paraselli, Yeeman K. Ramtohul, Thumkunta Jagadeeswar Reddy, Claudio Sturino, Lino Valdez, Jinglan Zhou
  • Patent number: 11591350
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: February 28, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
  • Patent number: 11584761
    Abstract: The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: February 21, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Angell, John E. Cochran, Benjamin J. Littler, David Siesel, Armando Urbina, Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
  • Publication number: 20220411410
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: February 22, 2021
    Publication date: December 29, 2022
    Inventors: Sara S. HADIDA RUAH, Peter D.J. GROOTENHUIS, Fredrick VAN GOOR, Jinglan Zhou, Brian BEAR, Mark T. MILLER, Jason McCARTNEY, Mehdi Michel Jamel NUMA, Xiaoqing YANG
  • Publication number: 20220372047
    Abstract: Compound (I), deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing are disclosed. Methods of treating cystic fibrosis using these compounds are also disclosed.
    Type: Application
    Filed: April 2, 2020
    Publication date: November 24, 2022
    Inventors: Alexander Russell ABELA, Sunny ABRAHAM, Corey Don ANDERSON, Vijayalaksmi ARUMUGAM, Jaclyn CHAU, Jeremy CLEMENS, Thomas CLEVELAND, Timothy A. DWIGHT, Bryan A. FRIEMAN, Peter GROOTENHUIS, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Paul KRENITSKY, Jason MCCARTNEY, Vito MELILLO, Mark Thomas MILLER, Alina SILINA, Johnny UY, Jinglan ZHOU
  • Publication number: 20220313698
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.
    Type: Application
    Filed: August 13, 2020
    Publication date: October 6, 2022
    Inventors: Alexander Russell Abela, Corey Don Anderson, Brett C. Bookser, Brett B. Busch, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Senait G. Ghirmai, Peter Grootenhuis, Anton V. Gulevich, Sara Sabina Hadida Ruah, Yoshihiro Ishihara, Haripada Khatuya, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Andreas Termin, Sara E. Swift, Johnny Uy, Carl V. Vogel, Jinglan Zhou
  • Publication number: 20220306606
    Abstract: Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Application
    Filed: October 20, 2021
    Publication date: September 29, 2022
    Inventors: Timothy Alcacio, Minson Baek, Peter Grootenhuis, Sara Sabina Hadida Ruah, Robert M. Hughes, Ali Keshavarz-Shokri, Rachel McAuley-Aoki, Jason McCartney, Mark Thomas Miller, Fredrick Van Goor, Beili Zhang, Corey Anderson, Thomas Cleveland, Bryan A. Frieman, Haripada Khatuya, Pramod Virupax Joshi, Paul John Krenitsky, Vito Melillo, Fabrice Jean Denis Pierre, Andreas P. Termin, Johnny Uy, Jinglan Zhou, Alexander Russell Abela, Brett Bradley Busch, Prasuna Paraselli
  • Patent number: 11453655
    Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: September 27, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Alexander Russell Abela, Timothy Alcacio, Corey Anderson, Paul Timothy Angell, Minson Baek, Jeremy J. Clemens, Thomas Cleveland, Lori Ann Ferris, Peter Diederik Jan Grootenhuis, Raymond Stanley Gross, Anton V. Gulevich, Sara Sabina Hadida Ruah, Clara Kuang-Ju Hsia, Robert M. Hughes, Pramod Virupax Joshi, Ping Kang, Ali Keshavarz-Shokri, Haripada Khatuya, Paul John Krenitsky, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Jean Denis Pierre, Yi Shi, Muna Shrestha, David Andrew Siesel, Kathy Stavropoulos, Andreas P. Termin, Fredrick F. Van Goor, Johnny Uy, Timothy John Young, Jinglan Zhou
  • Patent number: 11426407
    Abstract: The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: August 30, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Mark Thomas Miller, Corey Anderson, Vijayalaksmi Arumugam, Brian Richard Bear, Hayley Marie Binch, Jeremy J. Clemens, Thomas Cleveland, Erica Conroy, Timothy Richard Coon, Bryan A. Frieman, Peter Diederik Jan Grootenhuis, Raymond Stanley Gross, Sara Sabina Hadida-Ruah, Haripada Khatuya, Pramod Virupax Joshi, Paul John Krenitsky, Chun-Chieh Lin, Gulin Erdogan Marelius, Vito Melillo, Jason McCartney, Georgia McGaughey Nicholls, Fabrice Jean Denis Pierre, Alina Silina, Andreas P. Termin, Johnny Uy, Jinglan Zhou
  • Patent number: 11414439
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis by administering such modulators and pharmaceutical compositions, and processes for making such modulators.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: August 16, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Alexander Russell Abela, Jeremy J. Clemens, Peter Diederik Jan Grootenhuis, Sara Sabina Hadida Ruah, Yoshihiro Ishihara, Haripada Khatuya, Jason McCartney, Mark Thomas Miller, Fabrice Jean Denis Pierre, Joe Anh Tran, Jinglan Zhou
  • Publication number: 20220106331
    Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Application
    Filed: May 18, 2021
    Publication date: April 7, 2022
    Inventors: Jeremy J. Clemens, Alexander Russell Abela, Corey Don Anderson, Brett B. Busch, Weichao George Chen, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Senait G. Ghirmai, Peter Grootenhuis, Anton V. Gulevich, Sara Sabina Hadida Ruah, Clara Kuang-Ju Hsia, Ping Kang, Haripada Khatuya, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Andreas Termin, Johnny Uy, Carl V. Vogel, Jinglan Zhou
  • Publication number: 20220047564
    Abstract: This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof. (I) The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents.
    Type: Application
    Filed: November 13, 2019
    Publication date: February 17, 2022
    Inventors: David M. ALTSHULER, Corey Don ANDERSON, Bartlomiej BOREK, Weichao George CHEN, Jeremy J. CLEMENS, Thomas CLEVELAND, Timothy Richard COON, Bryan FRIEMAN, Peter GROOTENHUIS, Sara Sabina HADIDA RUAH, Brian J. HARE, Reshma KEWALRAMANI, Jason McCARTNEY, Mark Thomas MILLER, Prasuna PARASELLI, Fabrice PIERRE, Sarah M. ROBERTSON, Patrick R. SOSNAY, Sara E. SWIFT, Fredrick VAN GOOR, Tim YOUNG, Jinglan ZHOU
  • Publication number: 20220041621
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.
    Type: Application
    Filed: August 6, 2021
    Publication date: February 10, 2022
    Inventors: Jeremy J. Clemens, Brett C. Bookser, Thomas Cleveland, Timothy R. Coon, Michel Gallant, Peter Diederik Jan Grootenhuis, Sara Sabina Hadida Ruah, Julie Laterreur, Vito Melillo, Mark Thomas Miller, Prasuna Paraselli, Yeeman K. Ramtohul, Thumkunta Jagadeeswar Reddy, Claudio Sturino, Lino Valdez, Jinglan Zhou
  • Patent number: 11186566
    Abstract: Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: November 30, 2021
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Timothy Alcacio, Minson Baek, Peter Grootenhuis, Sara Sabina Hadida Ruah, Robert M. Hughes, Ali Keshavarz-Shokri, Rachel McAuley-Aoki, Jason McCartney, Mark Thomas Miller, Fredrick Van Goor, Beili Zhang, Corey Anderson, Thomas Cleveland, Bryan A. Frieman, Haripada Khatuya, Pramod Virupax Joshi, Paul John Krenitsky, Vito Melillo, Fabrice Jean Denis Pierre, Andreas P. Termin, Johnny Uy, Jinglan Zhou, Alexander Russell Abela, Brett Bradley Busch, Prasuna Paraselli
  • Patent number: 11066417
    Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: July 20, 2021
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy J. Clemens, Alexander Russell Abela, Corey Don Anderson, Brett B. Busch, Weichao George Chen, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Senait G. Ghirmai, Peter Grootenhuis, Anton V. Gulevich, Sara Sabina Hadida Ruah, Clara Kuang-Ju Hsia, Ping Kang, Haripada Khatuya, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Andreas Termin, Johnny Uy, Carl V. Vogel, Jinglan Zhou
  • Publication number: 20210139514
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.
    Type: Application
    Filed: April 5, 2019
    Publication date: May 13, 2021
    Inventors: Alexander Russell ABELA, Jeremy J. CLEMENS, Peter Diederik Jan GROOTENHUIS, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Haripada KHATUYA, Jason McCARTNEY, Mark Thomas MILLER, Fabrice Jean Denis PIERRE, Joe Anh TRAN, Jinglan ZHOU